Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
LI-FRAUMENI SYNDROME 1
|
0.700 | CausalMutation | CLINVAR | Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. | 11139324 | 2001 | |||||
LI-FRAUMENI SYNDROME 1
|
0.700 | CausalMutation | CLINVAR | Gastric cancer in individuals with Li-Fraumeni syndrome. | 21552135 | 2011 | |||||
Neoplastic Syndromes, Hereditary
|
0.700 | CausalMutation | CLINVAR | Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. | 26822237 | 2016 | |||||
Nasopharyngeal carcinoma
|
0.700 | CausalMutation | CLINVAR | ||||||||
GLIOMA SUSCEPTIBILITY 1
|
0.700 | CausalMutation | CLINVAR | ||||||||
Malignant neoplasm of large intestine
|
0.700 | CausalMutation | CLINVAR | ||||||||
BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 7
|
0.700 | CausalMutation | CLINVAR | ||||||||
LI-FRAUMENI SYNDROME 1
|
0.700 | CausalMutation | CLINVAR | High frequency of de novo mutations in Li-Fraumeni syndrome. | 19556618 | 2009 | |||||
LI-FRAUMENI SYNDROME 1
|
0.700 | CausalMutation | CLINVAR | The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. | 23161690 | 2013 | |||||
Neoplastic Syndromes, Hereditary
|
0.700 | CausalMutation | CLINVAR | Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. | 27683180 | 2017 | |||||
Osteosarcoma
|
0.700 | CausalMutation | CLINVAR | ||||||||
Li-Fraumeni Syndrome
|
0.800 | GeneticVariation | CLINVAR | ||||||||
Li-Fraumeni Syndrome
|
0.800 | GeneticVariation | UNIPROT | American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. | 24493721 | 2014 | |||||
Li-Fraumeni Syndrome
|
0.800 | GeneticVariation | UNIPROT | American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. | 17392385 | 2007 | |||||
Neoplasms
|
0.770 | GeneticVariation | BEFREE | Intriguingly, Cer-RUB nanomicelle treatments restored p53-dependent tumor suppression and sensitivity to cisplatin in OVCAR-3 ovarian cancer cells and xenograft tumors carrying p53 R248Q mutation. | 31645443 | 2020 | |||||
Neoplasms
|
0.770 | GeneticVariation | BEFREE | TP53 mutation analysis revealed an R248L mutation in both epithelial and mesenchymal components of 1 tumor.No TP53 rearrangements were identified. | 25704628 | 2015 | |||||
Neoplasms
|
0.770 | GeneticVariation | BEFREE | Interestingly, direct DNA sequencing of the paraffin-embedded tumor sample identified a novel R248Q mutation in the TP53 gene. | 22534715 | 2012 | |||||
Neoplasms
|
0.770 | GeneticVariation | CLINVAR | Mutant p53 in cancer: new functions and therapeutic opportunities. | 24651012 | 2014 | |||||
Neoplasms
|
0.770 | GeneticVariation | BEFREE | We show that the most common mutp53 allele R248Q (p53<sup>Q</sup>) exerts gain of function (GOF) and creates tumor dependence in mouse CRC models. mutp53 protein binds Stat3 and enhances activating Stat3 phosphorylation by displacing the phosphatase SHP2. | 30107178 | 2018 | |||||
Neoplasms
|
0.770 | GeneticVariation | BEFREE | Identification of TP53 R248Q in this tumor correlated with its aggressive clinical behavior. | 26260781 | 2015 | |||||
Neoplasms
|
0.770 | GeneticVariation | BEFREE | We conclude that in the AA-derived TNBC HCC70 cells mtp53 R248Q expression results in a causative tumor associated phenotype. | 26703669 | 2015 | |||||
Neoplasms
|
0.770 | GeneticVariation | BEFREE | Here we use a novel mutp53 mouse model expressing an inactivatable R248Q hotspot mutation (floxQ) to show that tumours depend on sustained mutp53 expression. | 26009011 | 2015 | |||||
Neoplasms
|
0.770 | GeneticVariation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 | |||||
Lymphoma
|
0.720 | GeneticVariation | BEFREE | This was associated with a twofold higher T-lymphoma proliferation in R248Q/- mice compared with G245S/- and null mice. | 23538418 | 2013 | |||||
Malignant neoplasm of breast
|
0.720 | GeneticVariation | BEFREE | Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. | 26703669 | 2015 |